Lyell Immunopharma amends bylaws to modernize shareholder proposals and align with DGCL

Lyell Immunopharma, Inc.

Removed requirement for nominated directors to provide support information except on independence.
Limited disclosure of supporting stockholders to those financially backing the proposal.
Added disclosure requirements for certain extrinsic arrangements in director nomination notices.
Clarified that updates to proposals (e.g., new nominees) constitute new proposals subject to same procedures.
Conformed notice provisions and stockholder list requirements to DGCL Sections 232 and 219.

item 5.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.